Executive Leadership

Michael Pehl, President and Chief Executive Officer

Mr. Pehl joined Immunomedics in December 2017 as President and CEO. His decades of strategic, commercial and operational leadership experience has helped reconfigure the company’s organization to support commercialization efforts. He has built effective organizations, managed portfolios (pre-clinical, marketed, lifecycle management) and led business development efforts. Additionally, Mr. Pehl was instrumental in growing portfolios through partnerships, alliances and product acquisitions.

Mr. Pehl dedicated his career to building compassionate, trusted relationships with patients and customers, and providing groundbreaking therapies to improve patient outcomes. His philosophy revolves around the patient, which is at the center of all that he does. He understands that for patients fighting disease, every day counts.

Year Joined: 2017

Experience:
Celgene Corporation 2006 – 2017
• President of Hematology & Oncology
• Global Marketing Head Hematology and Oncology
• Head of Hematology Europe
• Head of Region Central Europe
• General Manager Germany

AMGEN 1992 – 2006
• Head of Nephrology Marketing, Europe, Lucerne/Zug Switzerland
• Business Unit Head Nephrology Germany
• Marketing Director Germany (Oncology, Nephrology and Rheumatology)
• Several Sales and Marketing positions in Oncology, AMGEN Germany

Education:
Diploma in Molecular Biology, Ludwig Maximilian University of Munich

Brendan Delaney, Chief Commercial Officer

Brendan joined Immunomedics as Chief Commercial officer in November 2017. He has more than 22 years of global pharmaceutical and biotechnology experience, most recently serving as Vice President of U.S. Commercial Hematology-Oncology at Celgene Corporation. Brendan has led several successful product launches for blockbuster brands across both oncology and hematology. His deep commercial background and proven leadership will help drive Immunomedics to become a global oncology leader.

Year Joined: 2017

Experience:

Celgene Corporation 2011 – 2017
• VP of U.S. Commercial Hematology-Oncology
• VP of Global Marketing, Hematology franchise
• Executive Director of Global Marketing. Multiple Myeloma Franchise

Novartis 2006-2011
• Director, Global Chronic Myeloid Leukemia Franchise
• U.S. Marketing, Afinitor Launch Lead, Renal Cell Carcinoma

Genentech 2004-2006
• BioOncology Marketing and Operations

Education:
B.S. Biological Sciences, Rutgers University
M.B.A. Finance, The Stern School of Business at NYU

Usama Malik, Interim Chief Financial Officer, Chief Business Officer

Usama has over 25 years of experience in the technology, telecoms, and healthcare industries in key leadership roles ranging from corporate strategy, mergers and acquisitions, venture investing, product development, and operational management. He has worked on large-scale transformations across Fortune 500 companies, while helping to scale and grow numerous venture-backed and mid-sized organizations. He has lead key strategic efforts to bolster company balance sheets, take out costs, generate new revenue streams, raise capital, and lead multibillion dollar M&A transactions.

Year Joined: 2017

Experience:

Large and Mid-Cap Pharma, Biotech, and Healthcare Services Companies 2013-2017
• Senior Executive Advisor

Bridgewater Associates, 2012
• Senior Management

Pfizer 2007-2011
• Global VP Strategy, Innovation, and New Ventures

Booz & Co, 2003-2007
• Principal

KPMG Consulting 1998-2001
• Senior Manager

Education:
B.Sc, Electrical Engineering, University of Maryland at College Park
M.B.A. Finance, Strategy, Entrepreneurship, INSEAD

Dr. Morris Rosenberg, Chief Technology Officer

Dr. Rosenberg is a highly experienced biotechnology veteran with over 30 years’ experience in the development of therapeutic agents to treat a variety of human diseases. As a scientist, engineer and executive, he has played a key role in the development of several important commercially approved therapeutics.

Year joined: 2018

Experience:
Consultant, 2013 – 2017
• Consultant to the industry where he consulted for more than 25 companies focused on oncology drug development with a particular emphasis on antibody drug conjugates.

Seattle Genetics 2001 – 2013
• EVP of Development responsible for manufacturing, process development and supply chain management

Eli Lilly 1998 – 2001
• Director Biologics Process Development

Biogen 1990 – 1998
• Process Development, Associate Director Cell Culture Development

Invitron from 1987 – 1990
• Lab scientist and project manager

Education:
B.S. in Biology, B.S., M.S. and D.Sc. in Chemical Engineering, Washington University in St. Louis

Robert Iannone, Head of Research and Development and Chief Medical Officer

Robert joined Immunomedics in April 2018 as Head of Research and Development and Chief Medical Officer bringing extensive experience in pediatrics, pediatric-hematology-oncology and bone marrow transplantation. His most recent experience was with AstraZeneca as the Global Products Vice President, and subsequently as Senior Vice President and Head of Immuno-oncology, Global Medicines Development where he oversaw full development of late phase immune-oncology assets, including durvalumab (Imfinzi), tremelimumab and combinations with additional early and late phase assets, leading to approvals for Imfinzi in 2L+ urothelial carcinoma and stage 3 unresectable NSCLC after chemo-radiotherapy.

Year Joined: 2018

Experience:
AstraZeneca 2014-2018
• Head of Immuno-oncology, Global Medicines Development
• Vice President, Immuno-oncology Global Medicines Development

Merck 2008-2014
• Oncology Section Head, Clinical Research
• Senior Director, Upper Gwynedd Site Head for Experimental Medicine

Education:
Yale Medical School

Kurt Andrews, Chief Human Resources Officer

Kurt has 25 years of human resources experience, principally in the Life Sciences and Biotechnology industries.

Year Joined: 2018

Experience:
Amicus Therapeutics 2016-2018
• Senior Vice President, Global Human Resources

Valeritas Inc. 2013-2016
• Vice President, Human Resources

PTC Therapeutics 2004-2013
• Vice President, Human Resources

Vitex, Applied Biosystems and National Semiconductor
• Progressive human resources leadership roles

Education:
M.A., Labor and Industrial Relations, University of Illinois at Urbana-Champaign
B.A., Liberal Arts and Sciences, University of Illinois at Urbana-Champaign

Jared Freedberg, General Counsel

Jared oversees all aspects of Immunomedics’ legal, compliance and intellectual property functions. Jared brings more than 17 years of legal and corporate development experience in both pharmaceuticals and the pharma services industries, supporting the development and commercialization of a wide variety of products in numerous indication areas.

Year joined: 2018

Experience:
Mallinckrodt 2016-2018
• Vice President and group General Counsel

Covance 2001-2016
• Vice President Business Development and Strategy
• Vice President, Associate General Counsel/Vice President Corporate Development
• Vice President, Associate General Counsel/Senior Counsel/Assistant Counsel

Aptegrity Inc. 1999-2001
• Corporate Counsel and Global Director, Strategic Alliances

Littler, Mendelson, McCarter & English 1994-1999
• Attorney

Education:
J.D, Duke University School of Law
B.A., University of Pennsylvania